Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

By Global News Feed

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:

Continue reading here:
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

By Global News Feed

QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data

Read more:
QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

By Global News Feed

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Read more:
Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

By Global News Feed

MIAMI, FL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for higher quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced that it received a delinquency notification letter (“Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) on February 21, 2024 due to the Company’s non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Form 10-Q”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”).

See original here:
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call

By Global News Feed

ROCKVILLE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter of 2023 after the market closes on Thursday, March 7, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 7, 2024, at 4:30 pm ET.

Go here to see the original:
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal…

By Global News Feed

PARIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches today with seed finance from Pureos Bioventures and ND Capital. It is poised to clinically validate its highly innovative delivery platform by advancing two first-in-class late-stage preclinical drugs for wet and dry age-related macular diseases (AMD), including geographic atrophy (GA), major diseases of the elderly leading to blindness.

Excerpt from:
PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal...

→←